<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A case of 68 years old women suffering from <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0001903'>anemia</z:hpo>, <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and treated with <z:chebi fb="13" ids="50745">progestogen</z:chebi> due to endometrial <z:mpath ids='MPATH_159'>hypertrophy</z:mpath> is presented </plain></SENT>
<SENT sid="1" pm="."><plain>Initially she was admitted to a regional hospital because of progressive <z:mp ids='MP_0000746'>weakness</z:mp> and <z:hpo ids='HP_0002875'>exertional dyspnea</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Three months earlier she reported an episode of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002094'>dyspnea</z:hpo> and <z:hpo ids='HP_0100749'>chest pain</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>On the basis of clinical symptoms and perfusion lung scintigraphy <z:hpo ids='HP_0002204'>pulmonary embolism</z:hpo> (PE) was diagnosed </plain></SENT>
<SENT sid="4" pm="."><plain>Patient received i.v. <z:chebi fb="5" ids="28304">heparin</z:chebi> which was changed to s.c. nadroparine subcutaneously </plain></SENT>
<SENT sid="5" pm="."><plain>Platelet count dropped to 55,000'/ml on fifth day of treatment from initial level of about 200,000'/ml </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0011874'>Heparin induced thrombocytopenia</z:hpo> was diagnosed, <z:chebi fb="5" ids="28304">heparin</z:chebi> was stopped and <z:chebi fb="0" ids="9588">ticlopidine</z:chebi> was recommended </plain></SENT>
<SENT sid="7" pm="."><plain>After 3 weeks symptoms suggesting recurrent PE were observed </plain></SENT>
<SENT sid="8" pm="."><plain>The patient was transferred to National <z:e sem="disease" ids="C0041296" disease_type="Disease or Syndrome" abbrv="tb|tbc">Tuberculosis</z:e> and <z:e sem="disease" ids="C0024115" disease_type="Disease or Syndrome" abbrv="">Lung Diseases</z:e> Research Institute </plain></SENT>
<SENT sid="9" pm="."><plain>Recombinant hirudine (Refludan) was administrated (bolus 0.4 mg/kg and initial dose of infusion 0.1 mg/kg/h) overlapping with <z:chebi fb="0" ids="53766,53768,53769">acenocoumarol</z:chebi> from second day </plain></SENT>
<SENT sid="10" pm="."><plain>Dose of r-hirudine was adjusted to achieve APTT prolongation 1.5 to 2.5 times of mid-<z:mpath ids='MPATH_458'>normal</z:mpath> range </plain></SENT>
<SENT sid="11" pm="."><plain>During treatment with r-hirudine no <z:mp ids='MP_0001914'>bleeding</z:mp> and new thromboembolic complications occurred </plain></SENT>
<SENT sid="12" pm="."><plain>Platelets count remained within <z:mpath ids='MPATH_458'>normal</z:mpath> range </plain></SENT>
<SENT sid="13" pm="."><plain>After 14 days clinical improvement was observed, though symptoms of right ventricular overload and hypoxemia were still present after 6 months of treatment with oral <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> suggesting <z:hpo ids='HP_0011010'>chronic</z:hpo> thromboembolic <z:hpo ids='HP_0002092'>pulmonary hypertension</z:hpo> </plain></SENT>
</text></document>